Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 on May 23, 2025, to $2.33 on May 27, 2025, marking a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Rocket and certain of its o ...

Core Viewpoint - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the safety and clinical trial protocol of its RP-A501 treatment, particularly concerning Serious Adverse Events (SAEs) that occurred during the trial [1][2][4]. Group 1: Allegations and Misrepresentation - The lawsuit claims that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the risks associated with the clinical trial, including the death of participants [2][3]. - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to inflated stock prices based on misleading information [3][4]. Group 2: Impact of the Clinical Hold - On May 27, 2025, Rocket announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient experienced a Serious Adverse Event resulting in death, which was not disclosed to investors prior to the amendment [4]. - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% [5]. Group 3: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP is representing the investors in this case, emphasizing their long-standing expertise in securities litigation and commitment to protecting investor rights [5][6].

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to significant losses suffered by investors following misleading statements regarding the safety of its clinical trial for RP-A501 [2][4]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced scrutiny for its handling of clinical trial protocols and communication with investors [4]. Group 2: Legal Actions and Investigations - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - Faruqi & Faruqi encourages investors who suffered losses exceeding $50,000 between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. Group 3: Clinical Trial Issues - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event, including death, which was not disclosed to investors prior to the incident [5]. Group 4: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit due to allegations of misleading investors regarding the safety and protocol of its clinical trials for gene therapies [3][4]. Group 1: Company Overview - Rocket Pharmaceuticals is a late-stage biotechnology company focused on developing gene therapies for rare and serious diseases [2]. Group 2: Legal Allegations - The class action lawsuit claims that Rocket Pharmaceuticals provided updates on its Phase 2 trial of RP-A501 for Danon disease while making materially false statements and omitting critical adverse facts about the trial's safety [3]. - The lawsuit alleges that the company was aware of the risk of Serious Adverse Events (SAEs), including patient deaths, but did not fully inform investors [3]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol to include a new immunomodulatory agent without disclosing this change to shareholders [3]. Group 3: Impact of FDA Action - On May 27, 2025, Rocket Pharmaceuticals announced that the U.S. FDA had placed a clinical hold on the RP-A501 Phase 2 trial following the death of a participant treated under the amended protocol, which had not been disclosed to investors [4]. - Following this announcement, Rocket Pharmaceuticals' stock price experienced a decline [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [3][4]. Summary by Relevant Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) and participant deaths [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death linked to the trial, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [4]. - Shareholders who register will receive updates on the case's progress through portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements by companies [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the announcement of a clinical hold by the FDA [2][3]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths during the clinical trial [2]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - Following the FDA's announcement of a clinical hold on May 27, 2025, due to a SAE resulting in a participant's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Class Action Details - The class period for the lawsuit is defined as February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [3]. - Shareholders who register will receive updates on the case's progress through portfolio monitoring software [3]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit ...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=153696&from=3 CLA ...